PubRank

Philippa Easterbrook

Author PubWeight™ 94.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A whole-genome association study of major determinants for host control of HIV-1. Science 2007 15.19
2 Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002 10.03
3 Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009 3.68
4 Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004 3.20
5 Characterization of CD4(+) CTLs ex vivo. J Immunol 2002 3.10
6 Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009 2.82
7 Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis 2013 2.71
8 Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007 2.47
9 Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005 2.45
10 Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 2011 2.42
11 Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007 2.28
12 HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 2010 2.06
13 Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007 2.06
14 Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J Virol 2003 2.02
15 Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005 1.93
16 Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. BMC Health Serv Res 2009 1.82
17 Is antiretroviral therapy associated with symptom prevalence and burden? Int J STD AIDS 2006 1.67
18 HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor. J Exp Med 2004 1.60
19 Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS 2010 1.57
20 Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. AIDS 2004 1.38
21 Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol 2010 1.26
22 Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol 2002 1.25
23 Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 2009 1.20
24 HIV/AIDS-related stigma and discrimination: accounts of HIV-positive Caribbean people in the United Kingdom. Soc Sci Med 2008 1.19
25 Access and equity in HIV/AIDS palliative care: a review of the evidence and responses. Palliat Med 2005 1.11
26 Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS 2008 1.11
27 Strong TCR conservation and altered T cell cross-reactivity characterize a B*57-restricted immune response in HIV-1 infection. J Immunol 2006 1.09
28 Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS 2009 1.09
29 Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 2008 1.07
30 CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009 1.07
31 Sexual behaviors over a 3-year period among individuals with advanced HIV/AIDS receiving antiretroviral therapy in an urban HIV clinic in Kampala, Uganda. J Acquir Immune Defic Syndr 2011 1.00
32 Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3. J Acquir Immune Defic Syndr 2008 0.93
33 Characterization of an HLA-C-restricted CTL response in chronic HIV infection. Eur J Immunol 2010 0.93
34 Pain and symptom control in HIV disease: under-researched and poorly managed. Clin Infect Dis 2005 0.93
35 Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007 0.91
36 Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection. Blood 2013 0.89
37 Hyperimmunoglobulinemia and rate of HIV type 1 infection progression. AIDS Res Hum Retroviruses 2004 0.88
38 Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. AIDS 2009 0.88
39 "It took a piece of me": initial responses to a positive HIV diagnosis by Caribbean people in the UK. AIDS Care 2010 0.88
40 Sexual health and HIV in travellers and expatriates. Occup Med (Lond) 2007 0.87
41 Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms. Proc Natl Acad Sci U S A 2012 0.86
42 Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002 0.84
43 Coping with HIV: Caribbean people in the United Kingdom. Qual Health Res 2009 0.84
44 Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 2011 0.81
45 Occupational exposure to HIV and the use of post-exposure prophylaxis. Occup Med (Lond) 2007 0.81
46 Virological response to initial antiretroviral regimens containing abacavir or tenofovir. J Infect Dis 2009 0.81
47 The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. J Infect Dis 2005 0.80
48 Factors influencing lopinavir and atazanavir plasma concentration. J Antimicrob Chemother 2010 0.80
49 Herpesvirus saimiri-immortalized human lymphocytes: novel hosts for analyzing HIV type 1 in vitro neutralization. AIDS Res Hum Retroviruses 2002 0.76
50 Identification of a novel HLA B*57 restricted cytotoxic T-lymphocyte epitope within HIV-1 rev. AIDS 2006 0.76
51 Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa. AIDS 2016 0.76
52 Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy? J Infect Dis 2012 0.76
53 Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. J Acquir Immune Defic Syndr 2009 0.75
54 High levels of discordance between sequencing and serological subtyping in a predominantly non-B subtype HIV-1 infected cohort. J Clin Virol 2005 0.75
55 HIV and UN peacekeeping operations. AIDS 2003 0.75
56 Primary antiretroviral resistance in newly diagnosed patients with established heterosexually acquired HIV-1. AIDS 2002 0.75
57 HIV drug resistance in HIV-infected children. J Pediatr (Rio J) 2009 0.75